title: Pegylated interferon-α2a versus pegylated interferon-α2b in hepatitis C: reappraisal of effectiveness on the basis of trial sequential analysis.
authors.affiliation: aHTA Unit bDrug Committee, Regional Center for Pharmaceutical and Technical Services, 'Toscana Centro' Jurisdiction, Regional Health Service, Firenze, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Messori
authors.forename: Valeria
authors.initials: V
authors.lastname: Fadda
authors.forename: Dario
authors.initials: D
authors.lastname: Maratea
authors.forename: Sabrina
authors.initials: S
authors.lastname: Trippoli
authors.forename: Claudio
authors.initials: C
authors.lastname: Marinai
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a